DGHMC
ENZ

Dalton, Greiner, Hartman, Maher & Co’s Enzo Biochem, Inc. ENZ Stock Holding History

Dalton, Greiner, Hartman, Maher & Co’s Portfolio ENZ Stock Details ENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-80,000
Closed -$288K – 186
2019
Q3 		$288K Buy
+80,000
New +$283K 0.02% 184

Other funds holding ENZ

HFA
Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return
EGA
Evermore Global Advisors Summit, New Jersey $26.3M AUM 7.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FM
Fondren Management Houston, Texas $16.9M AUM 5.82% 1-Year Est. Return

Dalton, Greiner, Hartman, Maher & Co's ENZ Position: Q4 2019 in Review

Dalton, Greiner, Hartman, Maher & Co sold out of Enzo Biochem, Inc. (ENZ) in Q4 2019, closing a stake of 80,000 shares — an estimated $288K sold.

Dalton, Greiner, Hartman, Maher & Co first reported a position in ENZ in Q3 2019 and held it in 1 quarter. The position peaked at $288K in Q3 2019. 81 funds tracked by Wall St. Rank hold ENZ as of Q4 2019.

  • Dalton, Greiner, Hartman, Maher & Co reported no remaining Enzo Biochem, Inc. position as of Q4 2019 after selling out during the quarter.
  • Dalton, Greiner, Hartman, Maher & Co sold 80,000 Enzo Biochem, Inc. shares in Q4 2019, an estimated $288K.
  • Dalton, Greiner, Hartman, Maher & Co first reported a position in Enzo Biochem, Inc. in Q3 2019 and held it in 1 quarter.
  • Dalton, Greiner, Hartman, Maher & Co's Enzo Biochem, Inc. position peaked at $288K in Q3 2019.
  • 81 funds tracked by Wall St. Rank held Enzo Biochem, Inc. as of Q4 2019.

Based on Dalton, Greiner, Hartman, Maher & Co's 13F filing for Q4 2019, filed 15 Jan 2020.